Integra LifeSciences IART Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total Revenues by Product | |||||
| ENT | $166.37M+22.7% | $135.64M+264% | $37.28M+13.4% | $32.87M— | |
| Instruments | $206.47M+1.1% | $204.18M-4.0% | $212.65M+10.4% | $192.68M-13.3% | |
| Neurosurgery | $827.67M+3.0% | $803.82M-1.7% | $818.1M+3.0% | $794.02M-1.1% | |
| Private Label | $111.25M-4.4% | $116.33M+7.1% | $108.59M-17.4% | $131.41M+5.3% | |
| Wound Reconstruction | $323.49M-7.7% | $350.57M-6.3% | $373.99M-8.0% | $406.69M+3.6% | |
| Total Revenues by Geography | |||||
| Asia Pacific | $189.25M+7.2% | $176.61M-8.5% | $193.1M+9.4% | $176.48M-3.1% | |
| Europe | $162.67M+2.6% | $158.5M-4.1% | $165.22M-3.3% | $170.9M-10.7% | |
| Rest of World | $78.58M-5.0% | $82.74M+0.3% | $82.53M-1.1% | $83.48M— | |
| United States | $1.2B+1.0% | $1.19B+8.4% | $1.1B-2.3% | $1.13B+3.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Integra LifeSciences break its business down?
- Integra LifeSciences (IART) reports total revenues by business across 2 parts — Specialty Surgery and Tissue Reconstruction. Each is extracted from the segment footnotes and tracked over time.
- Where does Integra LifeSciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Integra LifeSciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
